The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Results from DETERMINATION: RVd with or without ASCT
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest data coming from the DETERMINATION study (NCT01208662). In patients with newly diagnosed multiple myeloma, this study investigated the effect of adding autologous stem cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib and dexamethasone – RVd), followed by lenalidomide maintenance therapy until disease progression. The study reported a longer progression-free survival (PFS) in patients treated with RVd plus ASCT, compared with RVd alone. The study also noted that maintenance until progression was of benefit to patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT
Scientific Founder: Oncopep, DCT
